Richard Furie

Rethinking the Benign Nature of Class II Lupus Nephritis

Jasmine Shwetar, Andrea Fava, Sarah Keegan, Philip M. Carlucci et autres

Introduction: Class II lupus nephritis (LN) is considered clinically benign, yet up to 50% of patients progress to more severe disease and no molecular characterization exists. We aimed to define the single-cell landscape of Class II LN and identify cellular and transcriptional …

us, il (code pays fourni par la source)

05 What defines success in lupus/lupus nephritis in 2026?

Richard Furie

Success is defined differently along the drug development path. In the earliest phase of drug development, the goals are to evaluate pharmacokinetics and confirm pharmacodynamics. Above all is safety. It is challenging for a small and short Phase I systemic lupus erythematosus …

us (code pays fourni par la source)

Obinutuzumab Induces Histological Remission and Deep Kidney Parenchymal B-Cell Depletion in Patients with Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY Trial

Richard Furie, Brad Rovin, Elsa Martins, Cary Austin et autres

Objectives The REGENCY trial ( NCT04221477 ) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). These exploratory analyses aimed to …

us, ch, ar, br, co, mx, pl, pe, gb (code pays fourni par la source)

Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit in Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results

Richard Furie, Brad Rovin, Jay Garg, Rachel Jones et autres

Objectives The Phase III REGENCY study ( NCT04221477 ) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when added to standard therapy (ST) in patients with active lupus nephritis (LN). There is no …

us, gb, mx, ch, ca, it, br, co (code pays fourni par la source)

Infusion-Related Reactions (IRRs) and Hematologic Events Associated with Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial

Richard Furie, Teresa Baczkowska, Amit Saxena, Imran Hassan et autres

Objectives The REGENCY ( NCT04221477 ) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus nephritis (LN). Insights related to IRRs and hematologic effects of OBI would help guide future …

us, pl, ca, gb, ch (code pays fourni par la source)

“More guidelines than rules”: reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al

Saira Sheikh, Karen H. Costenbader, Joan T. Merrill, Manzi Susan et autres

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

us, ca (code pays fourni par la source)

A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis

Richard Furie, Hans‐Joachim Anders, George Bertsias, Ana Delgado et autres

INTRODUCTION: Belimumab, approved for systemic lupus erythematosus (SLE) and lupus nephritis (LN) treatment, is a B-cell-modulating monoclonal antibody that selectively inhibits B-lymphocyte stimulator (BLyS) and downregulates autoreactive B-cells. Comparing belimumab's results from BLISS-LN (phase 3, ClinicalTrials.gov Identifier: NCT01639339) with other LN trial …

us, de, gr, gb, ie (code pays fourni par la source)

Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial

Eric F Morand, Victoria P Werth, Joerg Wenzel, Richard Furie et autres

au, us, de, ca, ch, it (code pays fourni par la source)

Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial

Eric F Morand, Maria Dall’Era, J Sanchez-Guerrero, David R. Pearson et autres

BACKGROUND: Toll-like receptors (TLR) 7 and 8 (TLR7/8) are activators of innate and adaptive immunity contributing to lupus pathogenesis. In Cohort B of WILLOW, a phase 2, randomised, placebo-controlled, double-blind, basket, dose-finding study, enpatoran, an oral small molecule inhibitor of TLR7/8, was …

au, us, ca, de, ch, it (code pays fourni par la source)

Systemic lupus erythematosus: Phase 3 clinical trials to watch

Sumatha Channapatna Suresh, Maryam Own, Richard Furie

us (code pays fourni par la source)

Outcome measures in systemic lupus erythematosus

Sumatha Channapatna Suresh, Richard Furie, Sonali Narain

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by fluctuating multisystem involvement, relapsing-remitting activity, and substantial risk of irreversible organ damage. Standardized disease activity indices have facilitated clinical trials and research, yet integration into clinical practice has not occurred for …

us (code pays fourni par la source)

PO:11:297 Kidney function preservation with belimumab in patients with lupus nephritis receiving MMF standard therapy in BLISS-LN: improved proteinuria, clinical outcomes and biomarkers for belimumab vs placebo

Brad H Rovin, Hans‐Joachim Anders, George K Bertsias, Ana R. Delgado et autres

Objectives Belimumab (BEL) is a B-cell modulating anti-BLyS mAb approved for SLE (2011) and LN (2020). BLISS-LN’s unique design (104-week registrational Phase 3 study; NCT01639339) investigating kidney outcomes with BEL allowed ISN/RPS class III or IV ± V or pure class V, …

us, de, gr, gb, ie (code pays fourni par la source)